ODYY - InvestorNewsBreaks - Odyssey Health Inc. (ODYY) Announces Positive Results from MAD Arm of Phase I Trial
Odyssey Health (OTC: ODYY), a company focused on developing unique, life-saving medical products, today announced the completion and safety findings from Cohort I of its Multi-Day Ascending Dosing (“MAD”) arm for its phase I clinical trial. The trial is administering PRV-002, Odyssey’s novel drug to treat concussion, to healthy human subjects. According to the update, MAD Cohort I subjects were dosed for five consecutive days, with the drug, PRV-002, safe and well tolerated. “As the head of drug development for the PRV-002 concussion treatment, I was very happy to see these positive safety results when dosing for multiple days,” said Dr. Jacob VanLandingham of Odyssey Health. “PRV-002 appears to be well-tolerated when given intranasally. If PRV-002 is found to be efficacious for concussed patients in the phase 2/3 trials, I believe that intranasal brain-targeting will be the key to its success. So far, the intranasal drug/device combination has functioned nicely and has been well-tolerated in the clinical setting.”
To view the full press release, visit https://ibn.fm/2cvid
About Odyssey Health Inc.
Odyssey Health is a medical company with a focus in the area of life-saving medical solutions. Odyssey’s corporate mission is to create, acquire and develop distinct assets, intellectual property and exceptional technologies that provide meaningful medical solutions. The company is focused on areas that have an identified technological advantage, provide superior clinical utility, and have a substantial market opportunity. For more information about the company, visit www.OdysseyHealthInc.com.
NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.